Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments
Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
Cholesteryl ester transfer protein inhibitors: From high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: A randomized phase 2 trial (ROSE)
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial (ROSE2)
The Evolving Role of Cholesteryl Ester Transfer Protein Inhibition Beyond Cardiovascular Disease